The world is racing to find safe and effective vaccines against COVID-19. And when we do, these vaccines must be made available to everyone who needs them regardless of nationality or wealth. Not only is this morally right but it is also the fastest way to end the pandemic. So as world leaders line up to make deals for COVID-19 vaccines candidates we want to know: **did this deal move us closer to, or further from, an equitable outcome?**

The Vaccine Access Test provides a framework to answer this question by evaluating deals between companies and countries using three metrics:

➔ **Prioritized**: Is this deal aligned with global guidelines on prioritizing allocation among at-risk populations?

➔ **Phased**: Does this deal allow for phased delivery of doses to ensure initial-supply is not monopolized?

➔ **Published**: Is the contracting processes transparent from start to finish?

Each metric is worth up to 2 points with the potential for 6 points total. **Here is how this deal stacks up.**

**DEAL SUMMARY**

**Parties:** AstraZeneca and Korea

**Date:** August 6, 2020

**Terms of Agreement:** SK Bioscience signed a trilateral memorandum of understanding with Korea’s Health Ministry and AstraZeneca agreeing to manufacture AstraZeneca’s experimental COVID-19 vaccine. The manufacturing contract, which begins this month, will last until early next year and could be extended depending on AstraZeneca’s success in development of the vaccine. South Korea will begin discussions with AstraZeneca to introduce the vaccine to the country.

<table>
<thead>
<tr>
<th>METRIC</th>
<th>SCORE</th>
<th>RATIONALE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prioritized</td>
<td>0</td>
<td>No doses have been specified.</td>
</tr>
<tr>
<td>Phased</td>
<td>0</td>
<td>The deal has not specified phased delivery. Ideally, deals would allow for other countries to benefit from the initial supply and tier delivery of subsequent supply as it becomes available.</td>
</tr>
<tr>
<td>Published</td>
<td>0</td>
<td>Neither Korea nor SK Bioscience have listed details about the terms of deal and pricing online. AZ has not disclosed their pricing model.</td>
</tr>
</tbody>
</table>

**Total Score: 0 out of 6**

This deal leaves little flexibility to ensure the initial supply of vaccines isn’t monopolized.

Subsequent deals could be improved by providing details about the doses, purchasing more closely against global population allocation guidelines, and phasing delivery. AstraZeneca could also disclose a break-down of how they arrived at their unit price, and what it costs to produce the vaccine.

[ONE.org/VaccineAccessTest](https://ONE.org/VaccineAccessTest)